Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study-authors' response.

Tytuł:: Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study-authors' response.
Autorzy:: Chauveau M; Department of Infectious Disease, CHU Hôtel-Dieu, Nantes, France.
Raffi F; Department of Infectious Disease, CHU Hôtel-Dieu, Nantes, France.; CIC UIC 1413 INSERM, CHU Nantes, France.
Allavena C; Department of Infectious Disease, CHU Hôtel-Dieu, Nantes, France.; CIC UIC 1413 INSERM, CHU Nantes, France.
Źródło:: The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Nov 01; Vol. 74 (11), pp. 3403-3404.
Typ publikacji:: Letter; Comment
Język:: English
Imprint Name(s):: Publication: 1997- : London : Oxford University Press
Original Publication: London, New York, Academic Press.
MeSH Terms:: Anti-HIV Agents*
HIV Infections*
Emtricitabine ; Humans ; Prospective Studies ; Rilpivirine ; Tenofovir
Substance Nomenclature:: 0 (Anti-HIV Agents)
99YXE507IL (Tenofovir)
FI96A8X663 (Rilpivirine)
G70B4ETF4S (Emtricitabine)
Entry Date(s):: Date Created: 20190820 Date Completed: 20200520 Latest Revision: 20200520
Update Code:: 20240105
DOI:: 10.1093/jac/dkz351
PMID:: 31424548
: Opinia redakcyjna

Comment on: J Antimicrob Chemother. 2019 Nov 1;74(11):3402-3403. (PMID: 31280307)

Informacja